Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

TD Cowen analysts said in a note to investors that the third quarter was the third time in five years that Exact Sciences, which sells the Cologuard colorectal cancer screening test, has missed ...

Exact Sciences' Q3 earnings report has led to a ... Exact's main sources of revenues are its Cologuard test, a "patient-friendly, non-invasive stool-based DNA screening test that utilizes a ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Revenue: US$708.7m (up 13% from 3Q 2023). Net loss: US$38.2m (down from US$794.0k profit in 3Q 2023). US$0.21 loss per share (down from US$0.004 profit in 3Q 2023). Revenue missed analyst ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...